heads up!
A new potential treatment for androgenic alopecia, also known as male pattern alopecia, is National clinical trials It will begin to test its safety and efficacy.
Supporters are amazed by VDPHL01, a non-hormonal tablet that is promising to restore hair without the hassle of topical treatment and the potentially serious side effects of hormonal medications.
“The FDA-approved only oral treatment for patterned hair removal emphasizes non-hormonals as it has a mechanism of action of hormones and is associated with hormonal side effects such as erectile dysfunction, reduced libido and suicidal thinking. ” Dr. Neil Saddick I said it in the post.
Sadick, clinical professor of dermatology at Weill Cornell Medical College, said:
There is no treatment for androgenic alopecia It will impact over 80 million Americans. The US Food and Drug Administration approved topical minoxidil (also known as Rogaine) and oral finasteride (brand name Propecia) to treat hair loss.
Here's what you need to know about VDPHL01:
What is VDPHL01?
VDPHL01 is hoked by veradermics, a biopharmaceutical company based in New Haven, Connecticut. It has been announced In December, it raised $75 million to fund the new trial.
Bellardemix has been recently developed “Modified Release” Oral Minoxidil Tablets. Sadick refused to say whether VDPHL01 contains minoxidil.
“Trial sponsor Belladelmicus is currently choosing not to disclose any additional information regarding drug formulations,” Saddick said.
“VDPHL01 can tell you that it has a unique profile, unlike current FDA-approved treatments related to cardiac activity and unwanted sexual side effects,” he continued.
VDPHL01 is being studied as a pill or twice daily. Saddick said preliminary phase 2 data revealed hair growth two months after treatment. This “encouragement” data should be available in the coming months, he noted.
Belladel Mix expects to apply for approval within a year of completion of the exam.
How does VDPHL01 differ from other treatments?
Finasteride, sold as Proscar or Propecia, was approved by the FDA in the 90s. Estimated 2.6 million I took finasteride in 2022.
Pills will be prevented Testosterone is converted to another hormone called dihydrotestosterone (DHT). High levels of DHT can cause hair follicles to shrink and lead to hair loss.
Finasteride reduces hair loss and promotes hair growth, but it is intended only for men and can cause potential side effects such as reducing erectile dysfunction, sexual impulses and depression.
Meanwhile, the FDA approved oral minoxidil in the 70s to treat hypertension and topical minoxidil in the 80s for hair loss.
Minoxidil increases blood flow to the hair follicles and stimulates hair growth.
Side effects of OTC MED include scalp irritation, unwanted facial hair growth, chest pain, fast heartbeat and dizziness.
When asked about potential side effects of VDPHL01, Saddick said the conversation was “best between research investigators and potential exam participants.”
Who can participate in the VDPHL01 trial?
Sadick's Manhattan office, Sadick Dermatology, Phase 2/3 clinical trial VDPHL01.
The goal is to register around 480 men on all research sites.
Saddick is looking for 18-65 healthy men who live in the New York area and experiences patterned hair removal. Applicants should be willing to maintain at least a quarter-inch long hair throughout the study.
Selected will be compensated for participation that includes 13 visits to Sadic Dermatology over approximately 13 months. Enrolled patients will receive VDPHL01 or placebo. visit phlstudy.com Alternatively, call (212) 772-7242 for more information or sign up.
VDPHL01 is also being studied in women Phase 3 clinical trials It is scheduled to start later this year.
